The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York Empower 503B Outsourcing Facility Serving Retail Pharmacies BPC 157 & TB 500 Blend 10mg 10mg Peptide Tech FDA to Consider Lifting Restrictions on Numerous Compounded Peptides Foley & Lardner The FDA just announced that they're taking steps to lift restrictions on 12 peptides including BPC 157 and TB 500 making them accessible through compounding pharmacies again. This is a HUGE step Last week @fda sends out clarification on who can and cannot compound #glp1 like #tirzeaptide and #semaglutide and this week ProRx 503b shuts down GLP 1 compounding while @martymakary is photographed holding bootleg #